The Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy drugs in development market research report provides comprehensive information on the therapeutics under development for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy and features dormant and discontinued products.

GlobalData tracks 72 drugs in development for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy by 70 companies/universities/institutes. The top development phase for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy is phase ii with 34 drugs in that stage. The Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy pipeline has 63 drugs in development by companies and nine by universities/ institutes. Some of the companies in the Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy pipeline products market are: Astex Pharmaceuticals, Nanchang University Affiliated Hospital One and CSPC Pharmaceutical Group.

The key targets in the Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy pipeline products market include Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8 (CD30L Receptor or Ki 1 Antigen or Lymphocyte Activation Antigen CD30 or CD30 or TNFRSF8), Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform (PI3K-Delta or Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Delta or PIK3CD or EC 2.7.1.137 or EC 2.7.1.153), and Histone Deacetylase (HDAC or EC 3.5.1.98).

The key mechanisms of action in the Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy pipeline product include Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform (PI3K-Delta or Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Delta or PIK3CD or EC 2.7.1.137 or EC 2.7.1.153) Inhibitor with seven drugs in Phase III. The Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy pipeline products include eight routes of administration with the top ROA being Intravenous and eight key molecule types in the Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy pipeline products market including Small Molecule, and Gene-Modified Cell Therapy.

Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy overview

Angioimmunoblastic T-cell lymphoma (AITL), previously known as immunoblastic lymphadenopathy, is a rare and aggressive form of peripheral T-cell lymphoma that originates from mature T cells in the immune system. AITL typically affects individuals in late adulthood and often presents with generalized symptoms including enlarged lymph nodes, fever, night sweats, weight loss, skin rashes, and an increased risk of infections. It is characterized by a specific pattern of lymph node changes, often accompanied by the presence of abnormal cells called Reed-Sternberg-like cells. Diagnosis of AITL involves a series of tests, including biopsies of enlarged lymph nodes, blood tests, imaging studies (such as CT scans), and sometimes genetic or molecular analyses to confirm the presence of characteristic markers or mutations associated with the disease.

For a complete picture of Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.